Emine Elif Ozkan

Sanliurfa Education and Research Hospital, Ourfa, Şanlıurfa, Turkey

Are you Emine Elif Ozkan?

Claim your profile

Publications (3)5.99 Total impact

  • Emine Elif Ozkan
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer database analysis indicates that prostate cancer is one of the most seen cancers in men meanwhile composing the leading cause of morbidity and mortality among developed countries. Current available therapies are surgery, radiotherapy and androgene ablation for prostate carcinoma. The response rate is as high nearly 90% however, most of these recur or become refractory and androgene independent (AI). Therefore recent studies intensified on molecular factors playing role on development of prostate carcinoma and novel treatment strategies targetting these factors and their receptors. Insulin-like growth factor-I (IGF-I) and its primary receptor insulin-like growth factor receptor-I (IGF-IR) are among these factors. Biologic functions and role in malign progression are primarily achieved via IGF-IR which is a type 2 tyrosine kinase receptor. IGF-IR plays an important role in mitogenesis, angiogenesis, transformation, apoptosis and cell motility. It also generates intensive proliferative signals leading to carcinogenesis in prostate tissue. So IGF-IR and its associated signalling system have provoked considerable interest over recent years as a novel therapeutic target in cancer. In this paper it is aimed to sum up the lately published literature searching the relation of IGF-IR and prostate cancer in terms of incidence, pathologic features, and prognosis. This is followed by a discussion of the different possible targets within the IGF-1R system, and drugs developed to interact at each target. A systems-based approach is then used to review the in vitro and in vivo data in the published literature of the following compounds targeting IGF-1R components using specific examples: growth hormone releasing hormone antagonists (e.g. JV-1-38), growth hormone receptor antagonists (e.g. pegvisomant), IGF-1R antibodies (e.g. CP-751,871, AVE1642/EM164, IMC-A12, SCH-717454, BIIB022, AMG 479, MK-0646/h7C10), and IGF-1R tyrosine kinase inhibitors (e.g. BMS-536942, BMS-554417, NVP-AEW541, NVP-ADW742, AG1024, potent quinolinyl-derived imidazo (1,5-a)pyrazine PQIP, picropodophyllin PPP, nordihydroguaiaretic acid Insm-18/NDGA). And the other end point is to yield an overview on the recent progress about usage of this receptor as a novel anticancer agent of targeted therapies in treatment of prostate carcinoma.
    Molecular and Cellular Endocrinology 09/2011; 344(1-2):1-24. · 4.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary renal synovial sarcomas (SS) are rare tumors of the kidney. Faria et al first described primary renal synovial sarcoma in 1999 (Mod Pathol 12:94A). In this paper we present a primary renal synovial sarcoma case and review the 41 primary renal synovial sarcoma cases reported to date. Primary renal synovial sarcomas can exist in either a monophasic or a biphasic pattern. The monophasic variant of primary renal synovial sarcoma is more common and tends to have a better prognosis than the biphasic variant. We present in this paper, a 68-year-old woman with primary renal synovial sarcoma. She presented with right flank pain and abdominal distention. Postoperative pathology of the 20 cm mass on magnetic resonance imaging showed histologic and immunochemical features of synovial sarcoma with coexisting spindle and epithelial cells. She underwent adjuvant ifosfamide and doxorubicin chemotherapy and was free of disease at 1 year after diagnosis. As a conclusion, physicians should be aware of the possibility of malignancy in cystic renal masses and that synovial sarcoma is one of the possibilities.
    Internal Medicine 01/2011; 50(15):1575-80. · 0.97 Impact Factor
  • Emine Elif Ozkan, Muhammet Emin Guldur, Ali Uzunkoy
    [Show abstract] [Hide abstract]
    ABSTRACT: Benign schwannoma is a very rare confronted entity in the liver. Only a very few cases have been reported in the medical literature. A 56-year-old woman was admitted to our hospital with epigastric pain. In the computed tomography scan a cystic mass was observed in the liver. The mass was resected with a prediagnosis of hydatid cyst; intraoperatively a 15x10x10 cm mass filled with hemorrhagic fluid was found. The histological examination confirmed the diagnosis of a benign schwannoma, proven by verocay bodies and a positive immunoreaction with the neurogenic marker S-100 protein.
    Internal Medicine 01/2010; 49(15):1533-6. · 0.97 Impact Factor